New hope for prostate cancer: drug combo aims to control resistant tumors
NCT ID NCT07538843
First seen Apr 28, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study looks at how well darolutamide (a newer drug) plus standard hormone therapy works in Chinese men whose prostate cancer has become resistant to earlier treatment but hasn't spread. About 800 men will take part, and researchers will check if their PSA levels drop very low within 6 months. The goal is to control the cancer and delay it from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
Multiple Locations, China
Conditions
Explore the condition pages connected to this study.